Table 6: Base-case results for pairwise indirect comparisons versus pazopanib (PPS-based analysis).

PazopanibaTrabectedinIfosfamideGemcitabine
+ docetaxel
Pazopanib versus trabectedinPazopanib versus ifosfamidePazopanib versus gemcitabine
+ docetaxel

Effectiveness (discounted)
 LYs1.3751.3341.3361.3730.0410.0390.003
 PFLYs0.5030.4610.4630.5000.0420.0400.003
 PPLYs0.8720.8740.8730.872−0.001−0.0010.000
 QALYs0.6920.6630.6520.6910.0290.0400.001
Costs (discounted), £
 Study medication10,73311,6995,6759,769−9655,059964
 Administration812,4916,5162,707−2,411−6,435−2,627
 Adverse events6533,4812,7061,685−2,828−2,053−1,033
 Other costs PFS5571,0801,082554−522−5253
 Other costs PPS10,46410,46610,46610,464−3−30
 Total22,48829,21726,44525,180−6,729−3,957−2,692

Cost per QALY gainedDominantDominantDominant

LYs: life-years; PFLYs: progression-free life-years; PFS: progression-free survival; PPLYs: postprogression life-years; PPS: postprogression survival; QALYs: quality-adjusted life-years.
Because a Markov methodology was used for the indirect comparison, the effectiveness and cost results are similar but not identical to the direct comparison with placebo.